The strong revenue ramp from the first FDA-approved MSC therapy is a clear de-risking event for Mesoblast's commercial model. With Q4 alone generating US$36M, the annualized run-rate already exceeds US$144M. Monitor the final audited figures and any guidance for FY2027 as label expansion catalysts (adult SR-aGvHD, IBD) remain on the horizon. The strong preliminary results reduce cash-burn concerns and support pipeline funding.
Price Chart
Executive Summary
Mesoblast reported Ryoncil net revenue of US$36M for Q4 and US$115M for FY2026 ending June 30, 2026. The filing is a preliminary estimate subject to audit, and management guided for continued revenue growth. The company also noted a strong capital position and a new five-year facility.
Key Facts
- Ryoncil net revenue of US$36 million for Q4 FY2026 (quarter ended June 30, 2026)
- Full-year FY2026 Ryoncil net revenue of US$115 million
- Results are preliminary estimates, subject to completion of year-end closing and audit procedures
- Management anticipates continued revenue growth in the coming fiscal year
- Company stated capital position is strong and operational activities are well funded through revenue growth
Financial Impact
Q4 Ryoncil net revenue of US$36M; full-year FY2026 net revenue of US$115M
Risk Factors
- Results are preliminary and subject to audit adjustments
- Single-product revenue concentration (Ryoncil) creates dependency risk
- Forward-looking statements about revenue growth are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000064 |
| Exhibit: exhibit991ryoncilsalesup.htm | 0001345099-26-000064 |
| Document: 0001345099-26-000064-index-headers.html | 0001345099-26-000064 |
| Document: 0001345099-26-000064-index.html | 0001345099-26-000064 |
| Document: 0001345099-26-000064.txt | 0001345099-26-000064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access